GSK.jpg” alt=”GSK” width=”320″ height=”173″ />

Denmark-based Genmab has signed an agreement with British drug-maker GlaxoSmithKline (GSK) and Swiss pharmaceutical company Novartis for the conditional transfer of ofatumumab collaboration contract from GSK to Novartis.

Ofatumumab is a monoclonal antibody, which is developed to target the CD20 molecule found on the surface of chronic lymphocytic leukaemia (CLL) cells and normal B lymphocytes.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The transfer of the agreement is in line with the arrangement between Novartis and GSK to acquire its oncology products.

Genmab CEO Jan van de Winkel said: “The collaborations with Novartis and GSK for this innovative therapeutic antibody will help ofatumumab reach its fullest potential, while improving cash flows.”

The deal will come into force after completion of the GSK/Novartis transaction, which is expected to be completed in the first half of 2015.

“The deal is said to reduce Genmab’s funding commitment by DKK570m ($95.7m).”

Novartis intends to develop and commercialise ofatumumab in oncology indications after the transfer is completed, while GSK would continue to develop and commercialise for autoimmune indications.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The latest deal helps Genmab avoid the payment of existing funding liabilities of DKK180m ($30m), as well as research fund and development costs for ofatumumab beyond 31 December.

The deal is said to reduce Genmab’s funding commitment by DKK570m ($95.7m).

Genmab plans to develop follow-on CD20 products including formats incorporating its DuoBody and HexaBody technologies, upon completion of the transfer of the collaboration.

Image: GlaxoSmithKline headquarters in Brentford, London, England. Photo: courtesy of Maxwell Hamilton.